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Abstract We have purified a nuclear protein from mouse 
cerebella that binds to single-stranded oligo-DNA of cAMP 
response element and is modulated by morphine treatment. 
Isolation of the cDNA clone showed that the nuclear protein 
(ssCRE-BP) was identical to Pura, a DNA binding protein for 
single-stranded purine-rich sequences that was originally isolated 
as a replication factor, ssCRE-BP/Pura and mRNA were 
abundant in the brain. The levels of ssCRE-BP/Pura and the 
transcript were not changed by chronic morphine treatment, 
however, the levels of an activator of ssCRE-BP/Pura, which is 
necessary for the DNA binding, may be modulated by the 
treatment. 
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1. Introduction 
The development of tolerance and dependence by chronic 
morphine administration has been well documented in rodents 
using different protocols such as analgesic assays, locomotor 
activities and withdrawal-induced jumping activities [1]. For 
example, naloxone-induced jumping in mice treated chroni- 
cally with morphine was used as a model for drug dependence 
[2]. Tolerance and dependence have been shown to continue 
for a certain period after morphine withdrawal. Since the 
long-term cellular modifications are thought to be associated 
with changes in protein synthesis [3], it has been speculated 
that the regulation of gene expression may be involved in drug 
tolerance and dependence. Recent studies have shown that 
neural activities are associated with changes of transcription 
factors that interact with specific cis-elements in the promoter 
region [4-6]. Morphine treatment has been shown to regulate 
c-fos expression in rat caudate putamen and phosphorylation 
of cAMP response element binding protein (CREB) in rat 
locus coeruleus [7,8]. 
We have recently found that the binding activity of a nu- 
clear factor (ssCRE-BP) from the cerebellum was modified by 
chronic morphine treatment [9,10]. In this report, we describe 
the purification of ssCRE-BP from mouse cerebellum and the 
isolation of cDNA encoding ssCRE-BP, and investigate the 
mechanism by which the DNA binding activity of ssCRE-BP 
is decreased. This protein was identified originally as a repli- 
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cation factor, termed Pura [11,12]. We discuss the implication 
of ssCRE-BP/Pura in morphine dependence in the brain. 
2. Materials and methods 
2.1. DNA-protein binding assays 
For all experiments, male ddY strain mice weighing 25-30 g were 
supplied with food and water ad libitum. Chronic morphine treatment 
consisted of injecting the mice subcutaneously twice daily for 8 days 
with morphine hydrochloride (Dainipponseiyaku, Osaka, Japan). The 
dose of morphine hydrochloride was doubled every day from 10 mg/ 
kg to 80 mg/kg in 4 days, and then a dose of 100 mg/kg was main- 
tained during the last 4 days. This treatment has been shown to in- 
duce tolerance and dependence in mice [13]. At appropriate intervals, 
mice were decapitated, and the brains were dissected. 
Gel shift assays were carried out as previously described [9]. 
2.2. Purification of ssCRE-BPIPurot 
Biotin-21-dUTP (Clontech Laboratories, Inc., CA) was incorpo- 
rated into the 3' terminus of the synthetic single-stranded oligonucleo- 
tide (5'-CTGGGGGCGCCTCCTTGGCTGACGTCAGAGAGA- 
GAG-3') using terminal deoxynucleotidyltransferase (Takara Shuzo 
Co., LTD., Kyoto, Japan). Reactions (100 lal) contained 100 mM 
sodium cacodylate (pH 7.0), 1 mM COC12, 0.1 mM DTT, 2 nmol 
oligonucleotides, 10nmol biotin-21-dUTP, and 20 U terminal trans- 
ferase, and were incubated at 37°C for 30 min, and stopped by heating 
to 75°C for 10 min. The biotinylated oligonucleotides were precipi- 
tated by adding 15 lag poly(dI-dC), 0.3 M NaC1, and 1 ml of ice-cold 
100% ethanol. The precipitate was dissolved in 100 ~tl of H20, and 
mixed with 500 lal of streptavidin agarose (Gibco BRL, Life Technol- 
ogies, Inc., MD) with agitation for 30 min. The binding of the bioti- 
nylated oligonucleotides to the streptavidin agarose was monitored by 
adding 32p-labeled oligonucleotides to the reaction buffer [14]. 
Nuclear extracts were prepared from 60 g of mouse cerebella s 
described previously [10]. Extracts (600 ml) were subjected to high 
speed centrifugation (100 000 × g for 1 h), concentrated with Amicon 
YM 100 ultrafiltration membranes (Amicon, Grace Company, Dan- 
vers, MA) to 60 ml, mixed with 6 mg poly(dI-dC), and applied on 5 ml 
of a DNA affinity column. After the column was washed with buffer 
A (20 mM 4-(2-hydroxyethyl)-l-piperazineethane-sulfonic acid- 
NaOH, pH 7.5, 20% glycerol, 0.2 mM EDTA, 0.5 mM phenylmethyl- 
sulfonyl fluoride, 0.5 mM DTT), containing 0.1 M NaC1, proteins 
were eluted with buffer A, containing 0.3, 0.6, and 1.0 M NaC1. 
Fractions eluted with 1.0 M NaC1 which contained ssCRE-BP/Purc~ 
were diluted to 0.1 M NaCI before application to a 1 ml Mono-Q 
FPLC column (Pharmacia LKB Biotechnology, Uppsala, Sweden) 
equilibrated with buffer A, containing 0.1 M NaCI. Following a 10 
min wash with the same buffer, elution was carried out at 0.5 ml/min 
using a linear gradient of 0.1 1.0 M NaCI over 30 min. DNA binding 
activity and purity of the fractions were measured by the gel shift 
assay and 10% SDS-polyacrylamide g l electrophoresis. 
2.3. Protein sequence analysis and cDNA cloning of ssCRE-BPIPurot 
The cDNA of ssCRE-BP/Pura was obtained as follows. The pro- 
tein in buffer A (phenylmethylsulfonyl fluoride was omitted), contain- 
ing 0.1 M NaC1 and 2 M urea, was digested with Achromobacter 
lyticus lysyl endopeptidase (Wako Pure Chemical Industries, Ltd., 
Osaka, Japan) at 30°C overnight. Enzyme to substrate ratio was at 
1:10 (w/w). The mixture of the products was applied to a reversed- 
phase column (2.1 × 150 mm, YMC-Pack MB-ODS, YMC Co., Ltd., 
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Kyoto, Japan) using a Waters HPLC system (Waters Associates, 
MA), eluted by a linear gradient from 0.1% trifluoroacetic acid in 
acetonitrile/H20, 1:99 (v/v) to 0.085% trifluoroacetic acid in acetoni- 
trile/H20, 60:40 (v/v), at a flow rate of 0.3 ml/min for 60 min at 
ambient emperature, and collected as individual chromatographic 
fractions by monitoring at 214 nm. The N-terminal sequences of pep- 
tides were determined using automated cycles of the Edman degrada- 
tion reaction with peptide sequencer (ABI-477A, Applied Biosystems). 
An aliquot of template DNA from a mouse brain Quick-Clone 
cDNA library (Clontech Laboratories, Inc., CA) was amplified by 
PCR with degenerate primers from peptide sequences. A 96 bp 
PCR product was obtained using the sense primer (5'-GT(AGCT)- 
GA(CT)AT(ACT)CA(AG)AA(CT)AA(AG)-3') and the antisense 
primer (5'-CTTGTT(GT)CC(GT)CC(AGT)GC(AGCT)CC(AGCT)- 
AC(CT)TC-3') which encoded two of the sequenced peptides. Ap- 
proximately 1.0x 106 plaques of a mouse brain Egtl0 cDNA library 
(Clontech) were screened by plaque hybridization at high stringency 
using the ct-32p-labeled PCR product as probe. DNA sequences were 
analyzed by the dideoxy chain termination method with an ABI 373A 
DNA sequencer (Applied Biosystems). 
2.4. Northern blot analysis 
Northern blot analysis was carried out according to the method of 
Maniatis et al. [15]. The probe used for Northern blot analysis was the 
95 bp fragment of ssCRE-BP/Purct cDNA (nucleotides 165-262) la- 
beled with [a-32p]dGTP, an antisense primer (5'-TCTTCAGG- 
AAGCGGCCCTTGGCGTTCTGCTTCACGTCCAGGTA-3') cor- 
responding to nucleotides 220-262 of ssCRE-BP/Purct cDNA, the 
777 bp PstI fragment as a template, and Klenow fragment. Total 
RNA was isolated from several tissues by the acid guanidinium thio- 
cyanate-phenol-chloroform method [16]. The amount of RNA was 
measured at OD260. 20 I.tg of the RNA samples were fractionated 
on 1% agarose gels containing formaldehyde and transferred to nitro- 
cellulose filters (Schleicher and Schuell). The blotted membrane was 
hybridized with a radiolabeled DNA probe in hybridization buffer at 
65°C for 17 h [17]. After hybridization, the filters were washed in 
1 × SSC at 71°C, dried, and autoradiographed. 
2.5. Western blot analysis 
Polyclonal antisera gainst ssCRE-BP/Purc~ were raised in rabbits 
by immunization with GST-ssCRE-BP/Pura fusion proteins. The 
anti-ssCRE-BP/Purot antibody was purified on immobilized GST- 
ssCRE-BP/Purct proteins. A bacterial expression vector encoding re- 
combinant GST-ssCRE-BP/Purtx fusion protein with GST was con- 
structed by subcloning 1.2 kb full-length cDNA of ssCRE-BP/Purct 
into the vector pGEX-2T (Pharmacia). The GST fusion protein was 
expressed in E. coli (DH5ct, Gibco BRL) and purified using a glu- 
tathione Sepharose column (Pharmacia). 
Nuclear extracts from mouse tissues were analyzed by Western blot 
as described previously [17]. Equal amounts of proteins (20 p.g) from 
each sample were fractionated on 10% SDS-PAGE and electrotrans- 
ferred to nitrocellulose filters (85A, Schleicher and Schuell). The filters 
were blocked with 1% skim milk (Gibco) in TS buffer (150 mM NaC1 
and 10 mM Tris-HC1, pH 8.0) and then incubated with the affinity 
purified antibody against ssCRE-BP/Pur~ (primary antibody) diluted 
in TS buffer containing 1% skim milk (1:100) for 1 h at room tem- 
perature. After washing with TST buffer (TS buffer containing 0.05% 
Tween 20) 4 times, the filters were incubated with horseradish perox- 
idase-conjugated goat antibody against rabbit IgG (Cappel) in TS 
buffer containing 1% skim milk (1:1000) for 1 h at room temperature. 
Then, after washing with TST 3 times and washing with TS buffer 
twice, the blotting was performed in the ECL system (Amersham) 
according to the protocol of the manufacturer. 
2.6. Immunofluorescence 
Mice were decapitated, and the brains were quick-frozen i  a pow- 
der of dry ice. The frozen brains, supported in OCT compound (Tis- 
sue Tek II, Miles), were sectioned in a cryostat chamber. The sections 
(16 ktm thick) were mounted on gelatin-coated glass slides as described 
previously [14], and incubated with the antibody against ssCRE-BP/ 
Purer (diluted at 1:100) in buffer A containing 100 mM NaC1, 20 mM 
Na2HPO4, 20 mM NaH2PO4, pH 7.4, at 4°C for 15 h. Then the 
sections were washed in buffer A twice and incubated with FITC- 
conjugated goat antibodies against rabbit IgG (Cappel, diluted at 
1:500) at 4°C for 15 h. For DNA staining with diamidinophenyl 
indole (DAPI), the sections were incubated with DAPI (2 Ixg/ml) in 
the buffer at room temperature for 1 h, and washed twice with the 
buffer. The sections were then examined and photographed under a 
fluorescence microscope (Zeiss). Cultured cell lines, NG108-15 mouse 
neuroblastoma×rat glioma cells, SK-N-SH human neuroblastoma 
cells, C6 rat glioma cells, and NIH3T3 mouse fibroblasts, were grown 
on tissue culture chamber slides (Nunc), washed with buffer A and 
fixed with 2% paraformaldehyde/0.1% Triton X-100 in buffer A for 30 
min at room temperature. The cells were washed with 1%o Triton X- 
100 in buffer A twice and then washed again with buffer A twice. The 
cells were incubated with the antibodies and DAPI. 
3. Results 
The single-stranded DNA binding protein ssCRE-BP was 
purified from 800 mouse cerebella using ultrafiltration, oligo- 
DNA agarose chromatography and ion exchange chromato- 
graphy on a Mono Q column. A 13 500-fold purification and 
20% recovery of the total ssCRE binding activity was ob- 
tained (Table 1). During the purification of ssCRE-BP/Purct, 
we found that addition of casein is required to restore the 
DNA binding activity of the purified ssCRE-BP/Purct in the 
gel shift assay. Analysis of molecular weight on a Superose 12 
column showed ssCRE-BP/Purct to elute with a molecular 
mass of ,'~ 140 kDa. When analyzed by SDS-PAGE and gel 
shift assays, the highly purified ssCRE-BP/Purc~ fraction 
yielded two silver stained bands corresponding to 40 and 38 
kDa. This indicates that ssCRE-BP/Purtx is composed of a 
dimer or oligomer in its native state. The fractions from the 
Mono Q column with ssCRE-BP/Purct DNA binding activity 
were digested with lysylendopeptidase to provide peptide for 
protein sequence. Eight different fragments were separated on 
reverse-phase HPLC, and the N-termini were sequenced by 
Edman degradation (data not shown). 
Degenerate oligonucleotides encoding these peptides were 
provided as primers for polymerase chain reactions (PCRs) 
using a mouse brain cDNA library as template and a PCR 
product with 96 bp was obtained. The mouse brain cDNA 
library was then screened using a 32p probe prepared from 
this PCR fragment; several overlapping partial cDNAs were 
obtained. An open reading frame encoding 322 amino acids 
predicted ssCRE-BP to be 35 kDa, and included all eight 
peptides deduced from the peptide sequencing. A Genbank 
data base search revealed that the cDNA sequence of mouse 
ssCRE-BP was identical to mouse Purr× [18]. 
Northern blot analysis was used to determine the size and 
tissue distribution of the mRNA encoding ssCRE-BP/Purct. 
The ssCRE-BP/Purct probe hybridized a 5 kb message in sev- 
eral tissues (Fig. la). We used 95 bp cDNA (nucleotides 165- 
262) instead of the 777 bp PstI fragment (nucleotides 165- 
941) of the ssCRE-BP/Purct cDNA [12], because the longer 
probe contained CAA repeats which produced non-specific 
hybridization. This short DNA probe hybridized mainly 
with the transcript of 5 kb. The 5 kb ssCRE-BP/Punx tran- 
script was abundant in the cerebral cortex and cerebellum. 
The transcript was also detected in striatum, hippocampus, 
thalamus, hypothalamus, pons, mesencephalon and medulla 
oblongata t lower levels. Examination of the effect of chronic 
morphine treatment on ssCRE-BP/Pura mRNA levels in 
these brain regions showed no significant influence by chronic 
morphine treatment (data not shown). 
To confirm the ssCRE-BP/Purct mRNA distribution and 
establish that the cloned gene is capable of binding to the 
ssCRE DNA probe, an expression vector that expresses a 
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Fig. 1. Northern blot and Western blot analyses of ssCRE-BP/Purc~ in mouse tissues. (a) Northern blot analysis was carried out according to 
the method of Maniatis et al. [15]. Arrows indicate the positions of 28S and 18S rRNAs. The lower panel shows the ethidium bromide staining 
of the gel. (b) Nuclear extracts (20 gg protein) from mouse tissues were used for Western blot analysis with the affinity purified antibody 
against GST-ssCRE-BP/Purc~. M indicates molecular size from markers. 
cloned ssCRE-BP gene as a fusion protein to the C-terminus 
of glutathione S-transferase (GST) was constructed. The 
GST-ssCRE-BP/Pura fusion protein formed a sequence-speci- 
fic complex with ssCRE DNA in a gel shift assay, confirming 
that the isolated cDNA encoded ssCRE-BP/Purc~. Further- 
more, the complex between ssCRE and nuclear extracts 
from the mouse cerebella which express sCRE-BP/Pura was 
supershifted when a polyclonal antibody against GST-ssCRE- 
BP/Pura fusion protein was added. As control, the complex 
band with GST-ssCRE-BP/Pura was also supershifted by the 
polyclonal antibody completely (data not shown). 
We examined the expression of the ssCRE-BP/Pura protein 
using Western blot analysis with the GST-ssCRE-BP/Purc~ 
antibody, ssCRE-BP/Pura was found to be widely expressed 
in the mouse brain, ssCRE-BP/Purc~ was abundant in the 
cerebral cortex and cerebellum and low levels were detected 
in testis (Fig. lb). Examination of the effect of chronic mor- 
phine treatment on the amount of ssCRE-BP/Pura in the 
mouse brain regions, such as cerebral cortex, cerebellum, 
striatum, hippocampus, thalamus, hypothalamus, pons, me- 
sencephalon and medulla oblongata, showed that ssCRE- 
BP/Pura was not significantly influenced by chronic morphine 
treatment in Western blot analysis (data not shown). These 
data were also confirmed by Northern blot analysis. Immu- 
nohistochemical study demonstrated ssCRE-BP/Purc~ protein 
expression in the Purkinje neurons and granular cells of the 
mouse cerebellum, and low expressions in the liver and heart 
(Fig. 2a). In the Purkinje neurons, ssCRE-BP/Pur~ was de- 
tected in the nucleus and cytoplasm of the cells, ssCRE-BP/ 
Pur~ was mainly observed in nuclei of glial cells of the mouse 
cerebellum at lower levels. In some glial cells, the expression 
was detected in both nuclei and cytoplasm. Similar data were 
obtained from cultured cell lines, ssCRE-BP/Pura was loca- 
lized in both the nucleus and cytoplasm of neuronal cell lines, 
but mostly in nuclei of C6 glioma cells (Fig. 2b); NIH3T3 
cells exhibited barely above background with this antibody. 
The signals of the fluorescence were decreased by the prein- 
cubation of the antibody with GST-ssCRE-BP/Pura fusion 
proteins (0.5 ~tg/ml) to background, but not with GST pro- 
teins. 
At each step of the protein purification, ssCRE-BP was 
monitored by the sequence-specific binding to the ssCRE 
Table 1 
Purification of ssCRE-BP 
Fraction Protein (mg) Spec. act. (cpmX 10-4ling) Total binding activity Yield (%) Fold purification 
(cpm × 10 -4) 
Nuclear extract 400 58 23 200 100 1 
Amicon YM 100 180 113 20 340 88 2 
Oligo DNA-agarose 0.05 148 770 7 439 32 2 565 
Mono Q 0.006 784160 4705 20 13 520 
Specific activity (Spec. act.) indicates the radioactivity ofthe complex band in the gel shift assays. After the step of oligo-DNA agarose, the binding 
activity was assayed in the presence of casein (1 gg). 
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Fig. 2. Immunofluorescence micrographs of mouse tissues and cultured cell lines. (a) The sections of mouse tissues were stained with DAPI 
(left panels) for DNA staining or the antibody against GST-ssCRE-BP/Puro~ (right panels); A and B, cerebellum; C and D, heart; E and F, 
liver. (b) The cells were stained with DAPI (left panels) or the antibody against GST-ssCRE-BP/Purct (right panels); A and B, NG108-15 cells; 
C and D, SK-N-SH cells; E and F, C6 cells; G and H, NIH3T3 cells. 
using gel shift assays. DNA binding activity in the 1.0 M 
NaC1 eluate from the affinity column was no longer detected, 
however, when a small quantity of the 0.3 or 0.6 M NaC1 
flow-through fraction from the column was added to a bind- 
ing mixture containing 1.0 M NaC1 fraction, the DNA bind- 
ing activity of affinity-purified ssCRE-BP/Puret was recovered. 
Since the 0.3 and 0.6 M NaC1 fractions had no DNA binding 
activity alone, this indicates that an activator is necessary for 
complex formation between ssCRE-BP/Purc~ and DNA. To 
assess the putative activator, a variety of proteins were tested 
for the ability to increase the DNA binding activity of ssCRE- 
BP/Pure¢. As shown in Table 2, casein was capable of substi- 
Table 2 
Effect of casein on the binding activity of ssCRE-BP 
Sample Binding activity 
Nuclear extract 324 + 11 
Nuclear extract + Casein 368 + 24 
Affinity fraction 17 + 5 
Affinity fraction + flow-through fraction 2108-+ 39 
Affinity fraction + casein 2254 + 33 
Affinity fraction + BSA 14 + 6 
Affinity fraction + histone 16+ 3 
Casein 0 
Casein, BSA and histone were added to the DNA binding assays at 
0.1 mg/ml except for the affinity chromatography flow-through frac- 
tion (0.3 and 0.6 M NaC1 eluates), which was used at 0.02 mg/ml. 
Binding activity was tested by a gel shift assay with 2 btl of nuclear 
extracts (0.7 mg/ml) or affinity fractions (1.5 lxg/ml). 
tuting for the activator in the DNA binding assay. Bovine 
serum albumin (BSA), histone and sodium pyrophosphate 
showed no significant increase in the DNA binding activity 
of ssCRE-BP/Purct. 
To determine whether the activator was involved in the 
decrease in the DNA binding activity of ssCRE-BP/Purct ob- 
served after chronic morphine treatment of mice, GST- 
ssCRE-BP/Purc~ with or without casein was added to the nu- 
clear extracts of cerebellum chronically treated with morphine 
(Fig. 3). Addition of GST-ssCRE-BP/Purtx (2.5 ng) to the 
nuclear extracts which contained approximately 0.5 ng of en- 
dogenous sCRE-BP/Purct resulted in two complex bands; the 
lower band was derived from the nuclear extract and the 
upper band was from GST-fusion protein (arrow in Fig. 3). 
The complex band formed with the morphine-treated nuclear 
extracts was weaker than the band with the control nuclear 
extracts (Fig. 3, lanes 4 and 5). The addition of excess casein 
to the control or morphine-treated nuclear extracts increased 
the DNA binding activity to a similar level (Fig. 3, lanes 8 and 
9). These data strongly suggest hat chronic morphine treat- 
ment decreased the DNA binding activity of ssCRE-BP/Purct 
by lowering the level or activity of the activator in the cere- 
bellum. 
4. Discussion 
The present data demonstrate that the sequence-specific 
DNA binding protein, ssCRE-BP/Purt~, is a neuronal and 
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Fig. 3. Effect of chronic morphine treatment on an activator required for the DNA binding activity of ssCRE-BP/Purc~. Gel shift assays were 
performed with 5 ~tl of nuclear extracts (NE) alone (lanes 2, 3), NE supplemented with 2.5 ng of GST-ssCRE-BP/Pure~ (lanes 4, 5) or NE plus 
1 gg of casein (lanes 8, 9). NE was prepared from the cerebellum of control mice (C) or morphine treated mice (M). Band shifts were not de- 
tected with ssCRE-BP/Purct alone (lane 6); the maximal binding activity of ssCRE-BP/Pura when extracts were supplemented with casein (lane 
7). The arrow indicates the complex band with GST-ssCRE-BP and oligo-DNA. Lane 1 shows free DNA. Results of the gel shift assay repre- 
sent the data from four independent experiments. 
glial-enriched protein. Pura protein was originally purified 
from HeLa cells based on its binding to a DNA replication 
zone of initiation [11,12]. This zone contains a GA-rich ele- 
ment which exists in several eukaryotic origins of DNA repli- 
cation and upstream promoter egions. Recent reports show 
that Pur~ can stimulate transcription of a quail clusterin gene 
and is a potent activator of early gene transcription [19]. It is 
possible that ssCRE-BP/Purc~ has a dual role in DNA replica- 
tion and in transcription, such as RAD25/ERCC3 protein for 
DNA repair and RNA polymerase II transcription [20,21]. 
The data that ssCRE-BP/Purc~ is abundant in the brain and 
is regulated by chronic morphine treatment indicate that 
ssCRE-BP/Pure~ acts as an important ranscription factor in 
the brain, ssCRE-BP/Pur~ binds to single-stranded CRE of 
the somatostatin gene promoter region and preliminary results 
in our laboratory indicate that this protein binds to the CRE 
region of the tyrosine hydroxylase gene promoter which con- 
tains a GA-rich sequence. The regulation of the DNA binding 
activity of ssCRE-BP/Pur~ is likely to influence the biosynth- 
esis of neuropeptides and catecholamine synthesis in the brain 
[22]. ssCRE-BP/Purct may bind to unknown promoter se- 
quences that regulate numerous cellular processes of the 
brain. The different distribution of ssCRE-BP/Pur~ in neuro- 
nal and glial cells may imply that ssCRE-BP/Pur~ is translo- 
cated from cytoplasm to nucleus to bind specific sequences of 
DNA by some signals or factors such as casein-like activators 
in the neurons, ssCRE-BP/Pur~ may be activated for replica- 
tion of DNA and cell division in the nucleus of the glial cells. 
We demonstrated that the binding of ssCRE-BP/Pur~ to 
single-stranded CRE was specifically activated by casein. 
Casein stimulates the DNA binding activity of CBF3, a yeast 
centromere DNA binding protein, and casein is able to sub- 
stitute for a flow-through fraction from affinity chromatogra- 
phy or E. coli cytosolic fraction [23]. Thus, the effect of casein 
on the DNA binding activity of ssCRE-BP/Purc~ seemed to be 
specific. Recent reports howed that ssCRE-BP/Pur~ interacts 
with viral transcription regulatory tumor antigen (TAg) of 
human JC polyomavirus (JCV) which induces demyelinated 
plaques within the brain of patients, and with the late gene 
transcription activator of JCV, YB-1, which inhibits the DNA 
binding activity of ssCRE-BP/Purc~ to the pur element [24]. 
ssCRE-BP/Pur~ can be associated with a variety of proteins 
and acquire different functions in the transcription and repli- 
cation in different cells. Because the amount of ssCRE-BP/ 
Pur~ does not seem to be affected by chronic morphine treat- 
ment, the DNA binding of ssCRE-BP/Purct is likely to be 
regulated by the activator in the brain. The distribution of 
the activator in the brain would explain why the decreased 
DNA binding activity of ssCRE-BP/Purc~ was observed only 
in the cerebellum by chronic morphine administration [10]. It 
is possible that the levels of the activator protein in the cere- 
bellum may be lower than in other brain regions limiting its 
susceptibility o morphine treatment. 
Isolation of cDNA clones for the activator and the produc- 
tion of antibody are required for investigating the regulation 
of the activator protein by morphine. The altered function of 
ssCRE-BP/Pur~ by the activator may lead to morphine de- 
pendence through the regulation of transcription of the genes 
that affect the production of neuropeptides and catecholamine 
synthesis. Further experiments will be required to elucidate 
the functions of ssCRE-BP/Purct and its activator in the de- 
velopment of morphine dependence. 
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